Verdú M1, Colomer A2, Román R2, Erill N2, Moreno A1, Cordón-Cardo C1,2, Puig X1,2.
1HISTOPAT Laboratoris & 2BIOPAT. Grup Assistència. Barcelona (Spain).
HER-2/neu is a critical marker in assessing the molecular profile of breast cancer, as it represents a target for therapeutic intervention. HER-2/neu gene amplification has been reported to be associated with treatment response. Immunohistochemistry (IHC) […]
Erill N1, Colomer A1, Verdú M2, Román R1, Vidal A2, Condom E2, Banús JM3, Cordón-Cardo C1,2, Puig X1,2.
1BIOPAT. Grup Assistència, 2HISTOPAT Laboratoris & 3ICUN. Institut Català d’Urologia i Nefrologia. Barcelona (Spain).
Mutations of the TP53 tumor suppressor gene and nuclear accumulation of abnormal p53 proteins are common in colon and bladder cancer, and have been associated […]
A. Colomer, N. Erill, M. Verdú, R. Román, A Vidal, X. Puig.
BIOPAT. Biopatologia Molecular, SL. Barcelona, Spain.
LOH 17p/TP53 and LOH 18q/DCC have been related to prognosis of colorectal adenocarcinomas. Since MSI-H tumors have a minor rate of TP53 mutations and rarely present allelic deletions, we intended to study these molecular features in a series of 197 […]
Anna Colomer Valero, Manuel Guix Pericas
BIOPAT. Biopatología molecular, S.L. Grup Assistència.
Anna Colomer1, Nadina Erill1, Montse Verdú2, Ruth Román1, August Vidal1,2, Xavier Puig1,2.
1BIOPAT, Biopatologia Molecular, Barcelona, Spain. 2Histopat Laboratoris, Barcelona, Spain.
Two different patterns have been described for colorectal tumorigenesis. The main one -affecting 85% of sporadic tumors- is based on the familial adenomatous polyposis (FAP) model, a multistep process that involves at least APC, K-RAS, DCC andTP53 genes. […]